| Expression pattern: |
UP |
| Associated gene: |
FTO, AGO2 |
| Associated microRNA: |
miR-607 |
| Biological function: |
promotes proliferation, migration, invasion, and tumor growth in NSCLC |
| Molecular mechanism: |
Acts as a miR-607 sponge via MRE to upregulate the miR-607 target FTO. |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); ceRNA regulation (promotes); m6A modification (other) |
| Detected method: |
Q
H
M
|
| Validation methods: |
Microarray; RNase R Treatment; RT-qPCR; divergent primers PCR; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; ISH (In Situ Hybridization); RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; MTT; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Western Blot; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
potential diagnostic and therapeutic marker / potential biomarker for NSCLC |
| Description: |
hsa_circ_0072309 (circLIFR), derived from LIFR, is upregulated in NSCLC/LUAD and mainly localizes to the cytoplasm. It promotes proliferation, migration, invasion and xenograft tumor growth by sponging miR-607 and thereby upregulating the miR-607 target FTO (an m6A demethylase), establishing a hsa_circ_0072309/miR-607/FTO oncogenic axis. |
| Confidence score: |
0.867 |